Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 381-386 , September 2009

Pharmacologic monitoring and determinants of intracytoplasmic drug levels

References 

  1. Savage DG, Antman KH. Imatinib mesylate – a new oral targeted therapy. The New England Journal of Medicine. 2002;346:683–693
  2. Goldman JM, Melo JV. Chronic myeloid leukemia – advances in biology and new approaches to treatment. The New England journal of medicine. 2003;349:1451–1464
  3. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008;1;111(3):1039–1043
  4. Druker BJ, Guilhot F, O'Brien SG, et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. The New England Journal of Medicine. 2006;355(23):2408–2417
  5. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. The Lancet Oncology. 2007 Nov;8(11):1018–1029Review
  6. Peng BM, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology. 2004;22:935–942
  7. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics. 2005;444:879–894
  8. Mahon FX, Belloc F, Lagarde V, et al. - MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368–2373
  9. Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics. 2008;83:258–264
  10. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. Journal of the National Cancer Institute. 2000 Oct 18;92(20):1641–1650
  11. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496–3499
  12. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–4028
  13. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clinical Cancer Research. 2003;9:625–632
  14. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British Journal Of Cancer. 2003;89:1855–1859
  15. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemotherapy and Pharmacology. 2004;53:102–106
  16. Guilhot F, Hughes TP, Cortes J, et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]). Blood. 2008;112:Abstract 447
  17. Forrest DL, Trainor S, Ryan R, et al. Cytogenic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Research. 2009;33:271–275
  18. Mahon F-X, Molimard M. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leukemia Research. 2009 Aug;33(8):1147–1148
  19. Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring. 2005 Oct;27(5):634–640
  20. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739–3745
  21. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108:697–704
  22. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064–4072
  23. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008 Sep 1;112(5):2024–2027
  24. Mahon FX, Molimard M, Foryciarz K, et al. Imatinib blood level testing: current perspectives and key questions. Submitted to European Haematology in press.

PII: S1521-6926(09)00069-3

doi: 10.1016/j.beha.2009.09.007

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 381-386 , September 2009

Article Tools

* Image Usage & Resolution